文献速递妇科母胎医学

基于扩展家族史的盆腔器官脱垂治疗风险

Risk of pelvic organ prolapse treatment based on extended family history.
PubMed 文献 · Am J Obstet Gynecol · 2020-01-15

本研究利用犹他州人口数据库进行回顾性人群研究,纳入453,522名女性,评估不同家族史模式(受累亲属数量、类型、治疗年龄及母系或父系来源)与盆腔器官脱垂治疗风险的关系。结果显示,风险随一级亲属受累数量增加、亲属治疗年龄提前及母系遗传而升高,约4%的女性基于家族史具有>2倍的治疗风险。

要点

  • 一级亲属受累数量越多,脱垂治疗风险越高:≥1个RR 2.36,≥2个RR 3.79,≥3个RR 6.26。
  • ≥3个三级亲属受累且无一级或二级亲属受累的风险与1个一级亲属受累相似。
  • 母系家族史的风险 consistently 高于同等父系家族史,但父系遗传仍有作用。

核心结论

  • 盆腔器官脱垂治疗风险随受累近亲和远亲女性数量增加、亲属治疗年龄提前及母系遗传而升高。

研究设计与样本

  • 回顾性人群研究,使用犹他州人口数据库,纳入453,522名女性,包括4,628名接受治疗(手术或子宫托)的脱垂患者及其15,530名一级亲属、33,782名二级亲属和66,469名三级亲属。

主要发现

  • 一级亲属≥1个受累的RR为2.36(95%CI 2.15-2.58),≥2个为3.79(95%CI 2.65-5.24),≥3个为6.26(95%CI 1.29-18.30)。
  • ≥3个三级亲属受累且无一级或二级亲属受累的风险与1个一级亲属受累相似。
  • 一级亲属治疗年龄越大,RR估计值越低。
  • 母系家族史阳性的个体风险 consistently 高于同等父系家族史,但父系遗传仍有作用。
  • 约4%的研究女性基于家族史具有>2倍的治疗风险,被视为高风险。

关键数值与推荐

  • 一级亲属≥1个受累:RR 2.36(95%CI 2.15-2.58);≥2个:RR 3.79(95%CI 2.65-5.24);≥3个:RR 6.26(95%CI 1.29-18.30)。
  • ≥3个三级亲属受累且无一级或二级亲属受累的风险与1个一级亲属受累相似。
  • 约4%的女性基于家族史具有>2倍治疗风险。

临床怎么用

  • 临床询问盆腔器官脱垂家族史时,应扩展至远亲、受累亲属数量、治疗年龄及母系或父系来源,以更准确评估风险。
  • 基于家族史识别高风险女性(如>2倍风险),可能有助于遗传研究和风险降低策略的探索。

局限性

  • 回顾性研究设计可能引入偏倚。
  • 使用犹他州人口数据库,结果外推至其他人群需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Family history of pelvic organ prolapse among first-degree relatives is an established risk factor for pelvic organ prolapse; however, consideration of the constellation of family history that extends to distant relationships allows for more accurate determination of risk and may improve pelvic organ prolapse risk prediction estimates. OBJECTIVE: The purpose of this study was to assess risk for pelvic organ prolapse treatment based on varying family histories of pelvic organ prolapse and included number and types of affected relatives, ages of relatives at pelvic organ prolapse treatment, and whether the family history is of maternal or paternal origin. STUDY DESIGN: This was a retrospective, population-based study that involved the Utah Population Database, which is a population resource that includes extensive genealogy information linked to medical records. The study population included 453,522 total women: 4628 women with a diagnosis of treated (surgical or pessary) pelvic organ prolapse and their 15,530 first-degree relatives; 33,782 second-degree relatives, and 66,469 third-degree relatives. We estimated relative risk of treated pelvic organ prolapse based on specific family history constellations. RESULTS: Relative risk estimates increased with a family history of increasing numbers of treated first-degree relatives with pelvic organ prolapse (first-degree relatives, ≥1 [relative risk, 2.36; 95% confidence interval, 2.15-2.58], first-degree relatives, ≥2 [relative risk, 3.79; 95% confidence interval, 2.65-5.24], and first-degree relatives, ≥3 [relative risk, 6.26; 95% confidence interval, 1.29-18.30]). Having a family history of ≥3 affected third-degree relatives (eg, first cousins) and no affected first- or second-degree relatives was similar in risk to having 1 affected first-degree relative. Relative risk estimates decreased with increasing age of treatment for first-degree family members. Risks in individuals with a positive maternal family history for pelvic organ prolapse were consistently higher than risks in individuals with equivalent paternal family history, but paternal inheritance still played a role. Approximately 4% of the total studied female population was found to have a >2-fold risk of being treated for pelvic organ prolapse and is considered high-risk based on their family history. CONCLUSION: We provide estimates for treated pelvic organ prolapse based on an extensive family history of pelvic organ prolapse using a large population-based sample. Risk for treated pelvic organ prolapse increased with increasing numbers of affected close and distant female relatives, earlier age of pelvic organ prolapse treatment in relatives, and maternal inheritance. These risk estimates may be useful for genetic studies and investigation of risk reduction strategies in those at highest risk for pelvic organ prolapse.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Allen-Brady K, Norton PA, Hill AJ, et al. Risk of pelvic organ prolapse treatment based on extended family history. Am J Obstet Gynecol. 2020. PMID: 31954153. doi:10.1016/j.ajog.2019.12.271

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。